Document is current
Any future updates will be listed below
-
Authors
He, Lanfen
Mei, Huazhen
Gu, Yan
Liu, Zeng
Yang, Lian
Li, Xiaolu
Wang, Xiaofeng
Xu, Ting
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct07049172 at ClinicalTrials.govDocuments that mention this clinical trial
Combined impact of rituximab and target care on efficacy, quality of life, adverse reactions and recurrence rate in children with nephrotic syndrome: a randomized controlled trial
https://doi.org/10.1186/s12887-025-06070-0
-
Funding
Funding for this research was provided by:
Wuhan Medical Research Project in 2019 (WX19Q09, WX19Q09, WX19Q09, WX19Q09, WX19Q09, WX19Q09, WX19Q09, WX19Q09)
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 14 August 2025
First Online: 24 September 2025
Declarations
:
: The current study was conducted in accordance with the Helsinki Declaration of the World Medical Association and approved by the Ethics Committee of Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Center). Informed consent was obtained from the guardians of all the study subjects before enrollment, and assent was obtained from children capable of understanding.
: Not applicable.
: The authors declare no competing interests.
: This trial was registered with ClinicalTrials.gov (Identifier: NCT07049172).
: The full trial protocol can be accessed from the corresponding author on reasonable request.
